Elekta AB (publ) (EKTA B.ST) Osake Kurssi

Elekta AB (publ) is primarily active in the medical technology industry.

The main competitors of Elekta AB (publ) in the market include Varian Medical Systems, Accuray Incorporated, and Siemens Healthineers.

Elekta AB (publ) is a renowned company with a rich history and background. Established in 1972, Elekta specializes in developing advanced technology and comprehensive treatment solutions for cancer and brain disorders. Headquartered in Stockholm, Sweden, the company has expanded globally, with a presence in more than 100 countries. Elekta's innovation in radiation therapy, radiosurgery, and brachytherapy has revolutionized medical procedures, improving patient outcomes worldwide. With a commitment to precision and innovation, Elekta continues to collaborate with leading experts in healthcare, offering state-of-the-art solutions to enhance the quality of patient care and contribute to life-saving advancements in the field of oncology and neurosurgery. Overall, Elekta AB (publ) is a leading force in the medical technology sector, dedicated to transforming cancer care and neurological treatments.

Elekta AB (publ) has achieved several significant milestones in its trajectory. Over the years, the company has pioneered innovative solutions in the field of radiation therapy and precise neurosurgery. Elekta AB (publ) introduced the revolutionary Elekta Synergy, a state-of-the-art radiation treatment system that enables accurate targeting of tumors while minimizing damage to surrounding healthy tissues. Furthermore, the company developed the Leksell Gamma Knife, a non-invasive radiosurgery system for treating brain disorders with exceptional precision. Elekta AB (publ) continues to expand its global presence and collaborate with leading healthcare institutions, solidifying its position as a trusted provider of advanced medical technology solutions.

Elekta AB (publ) is primarily present in various countries and regions around the world. The company has a global presence, with a strong focus in North America, Europe, and Asia Pacific. Elekta AB (publ) operates in numerous countries, including the United States, Sweden (where it is headquartered), Germany, the United Kingdom, France, China, Australia, and many others. With its innovative medical technology solutions, Elekta AB (publ) continues to expand its presence and serve customers in the healthcare industry across diverse regions, making a significant impact in the field of radiation therapy and neurosurgery.

Elekta AB (publ) represents a company philosophy centered around innovation, quality, and patient care. With a dedicated focus on advancing cancer treatment and improving patient outcomes, Elekta AB (publ) strives to provide state-of-the-art technology and solutions in radiation therapy and radiosurgery. They are committed to developing cutting-edge medical devices and software systems that enable precise and personalized cancer treatment options. Elekta AB (publ) values collaboration, integrity, and a customer-centric approach, ensuring that patients and healthcare professionals have access to the best possible treatment solutions. With a strong global presence, Elekta AB (publ) continues to drive advancements in cancer care worldwide.

Analyytikot asettavat tällä hetkellä Elekta AB (publ)-osakkeelle keskimääräisen tavoitehinnan 56,90 SEK (mediaani: 54,06 SEK), mikä merkitsee +7,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 21 analyytikkoarvioon.

Elekta AB (publ) Analyytikkojen kursstavoitteet 2026

21 analyytikkoa arvioi tällä hetkellä Elekta AB (publ)-osaketta: 5 suosittaa ostoa, 7 pitoa ja 9 myyntiä.

Elekta AB (publ) Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Elekta AB (publ)-osake noteerataan hintaan 4,73 EUR (52,90 SEK).

Elekta AB (publ)-osake (EKTA B.ST) on listattuna 8 pörssissä, muun muassa: London (0O5H.L), Frankfurt (EJXB.F), München (EJXB.MU), Düsseldorf (EJXB.DU), Stockholm (EKTA B.ST).

Elekta AB (publ) is a globally leading company in the development and production of clinical systems for cancer treatment and neurological disorders. The company was founded in 1972 in Stockholm, Sweden, and has been listed on the Stockholm Stock Exchange since 1994. The core business of Elekta includes the planning and delivery of devices and software used in the treatment of cancer and neurological disorders. Elekta offers a variety of products and solutions tailored to the needs of clinics and hospitals worldwide. One of Elekta's main business areas is radiation therapy. The company offers innovative devices such as Elekta's linear accelerators, which generate high-speed particles to target the tumor. Elekta has also developed advanced imaging technology to assist doctors in diagnosis and determining the appropriate treatment method. Another important business area for Elekta is neurological therapy. Here, Elekta has developed devices for accurate diagnosis and treatment of brain tumors, Parkinson's disease, and epilepsy, among others. The offering is complemented by a wide range of software solutions that facilitate treatment planning and monitoring. Elekta works closely with doctors and research institutions to develop innovative solutions that help patients improve their health. Elekta has directed its research and development capacities towards creating new technologies that will further improve cancer treatment in the future. An example is the advanced "Unity" technology, which enables accuracy 30 times higher than conventional radiation. Elekta also has a wide network of service centers to ensure customer support. These facilities provide customers with the solutions they need to facilitate their work and improve patient care. Elekta's business model focuses on the needs of hospitals and clinics worldwide. With its offering of innovative devices and software solutions, Elekta emphasizes quality and technical excellence to meet the needs of customers and patients. The company has gained a global reputation for innovation and outstanding products and is known in the industry for its customer orientation. Overall, Elekta is a leading provider of clinical systems for cancer treatment and neurological disorders. With the continuous development of innovative technologies and products, as well as a strong network of service centers, Elekta is well positioned to consolidate its position in the global health market.

liikevaihto Elekta AB (publ) on 16,72 Mrd. SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

voitto Elekta AB (publ) on −520,00 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Elekta AB (publ):n hinta-voitto-suhde (P/E) on tällä hetkellä −38,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Elekta AB (publ)-osakkeen arvostusta.

Elekta AB (publ):n hinta-myynti-suhde (P/S) on tällä hetkellä 1,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Elekta AB (publ)-osakkeen arvostuskennuslukuna.

Elekta AB (publ):n Eulpool-laatuscore on 0/10.

Elekta AB (publ):n ISIN on SE0000163628. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Elekta AB (publ):n WKN on 896279. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Elekta AB (publ):n ticker on EKTA B.ST. Tämä pörssinoteeraus käytetään Elekta AB (publ)-osakkeiden kauppaan pörssissä.